Neuropathic pain, a distressing and debilitating disorder, is still poorly managed in clinic. Opioids, like morphine, remain the mainstay of prescribed medications in the treatment of this disorder, but their analgesic effects are highly unsatisfactory in part due to nerve injury-induced reduction of opioid receptors in the first-order sensory neurons of dorsal root ganglia. G9a is a repressor of gene expression. We found that nerve injury-induced increases in G9a and its catalyzed repressive marker H3K9m2 are responsible for epigenetic silencing of Oprm1, Oprk1, and Oprd1 genes in the injured dorsal root ganglia. Blocking these increases rescued dorsal root ganglia Oprm1, Oprk1, and Oprd1 gene expression and morphine or loperamide analgesia and prevented the development of morphine or loperamide-induced analgesic tolerance under neuropathic pain conditions. Conversely, mimicking these increases reduced the expression of three opioid receptors and promoted the mu opioid receptor-gated release of primary afferent neurotransmitters. Mechanistically, nerve injury-induced increases in the binding activity of G9a and H3K9me2 to the Oprm1 gene were associated with the reduced binding of cyclic AMP response element binding protein to the Oprm1 gene. These findings suggest that G9a participates in the nerve injury-induced reduction of the Oprm1 gene likely through G9a-triggered blockage in the access of cyclic AMP response element binding protein to this gene.
Introduction
Neuropathic pain is a distressing and debilitating disorder. 1 It is characterized by spontaneous ongoing or intermittent burning pain, an enhanced response to noxious stimuli (hyperalgesia), and pain in response to normally innocuous stimuli (allodynia). Currently, this disorder is still poorly managed. Opioids, like morphine, remain the mainstay of prescribed medications in the treatment of neuropathic pain. However, a majority of neuropathic pain patients show unsatisfactory pain relief. 2 They often require repeated and prolonged administration of higher doses of opioids. However, such opioid regimens lead to nausea, constipation, respiratory depression, opioid analgesic tolerance and hyperalgesia, respiration inhibition, and additional side-effects. 3 These adverse side effects significantly limit opioid use in neuropathic pain patients. Studies on neurobiological mechanisms of neuropathic pain suggest that nerve injury-induced reduction of opioid receptor mRNA and protein expression in the injured dorsal root ganglion (DRG) may be responsible, at least in part, for the decreased analgesic effects of opioids in neuropathic pain patients. [4] [5] [6] [7] Therefore, an understanding of how nerve injury drives DRG opioid receptor reduction may improve opioid analgesic efficacy and propose novel therapeutic strategies for managing neuropathic pain.
Epigenetic modifications including histone methylation control gene expression. 8 The histone methyltransferase G9a causes dimethylation on histone H3 on lysine residue 9 (H3K9me2), resulting in condensed chromatin and gene transcriptional repression. 9, 10 G9a has recently been associated with nerve injury-induced epigenetic silencing of mu opioid receptor (MOR) in DRG. 11 However, whether G9a also participates in the nerve injury-induced downregulation of other opioid receptors in the DRG is unclear. Furthermore, how G9a participates in nerve injury-induced DRG MOR reduction is still unknown.
Here, we first confirmed whether nerve injury-induced increases in G9a and its catalyzed repressive marker, H3K9me2, were responsible for nerve injury-induced reductions of MOR as well as kappa opioid receptor (KOR) and delta opioid receptor (DOR) in the injured DRG. We then examined whether these increases were associated with the enhancement of MOR-gated primary afferent neurotransmitter release and the decrease of MOR-mediated analgesia following peripheral nerve injury. Finally, we elucidated the mechanism of how G9a leads to DRG MOR downregulation under neuropathic pain conditions.
Materials and methods

Animal preparations
C57BL/6 J wild-type mice, Avil
Cre/þ mice, and G9a fl/fl mice and Sprague Dawley (SD) rats were used in this study. G9a fl/fl mice (provided by Dr. Eric J Nestler, Icahn School of Medicine at Mount Sinai, New York, USA) were fully backcrossed to C57BL/6 J mice and were homozygous for a floxed G9a allele. Male Avil Cre/ þ mice (provided by Dr. Fan Wang, Duke University Medical Center, Durham, NC) were crossed with G9a fl/ fl mice to obtain G9a conditional knockout (G9aKO) mice. All animals were kept in a standard 12-h light/ dark cycle, with water and food pellets available ad libitum. Male mice weighing 25-30 g and male rats weighing 250-300 g were used for behavior testing. All procedures used were approved by the Animal Care and Use Committee at Rutgers New Jersey Medical School and are consistent with the ethical guidelines of the US National Institutes of Health and the International Association for the Study of Pain. All efforts were made to minimize animal suffering and to reduce the number of animals used. All of the experimenters were blind to treatment condition.
DRG microinjection
DRG microinjection was carried out as described 12, 13 with minor modification. Briefly, a midline incision was made in the lower lumbar back region, and the L 3 and/or L 4 articular processes were exposed and then removed with small ronguers. After the DRG was exposed, viral solution (0.5-1 ml) was injected into one site in the L 3 and/or L 4 DRGs with a glass micropipette connected to a Hamilton syringe. The pipette was removed 10 min after injection. The surgical field was irrigated with sterile saline and the skin incision closed with wound clips. The injected mice displayed no sign of paresis or other abnormalities. The immune responses from viral injection were thus minimal.
Neuropathic pain models
A mouse neuropathic pain model of unilateral L 4 spinal nerve ligation (SNL) was carried out as described previously.
14 Briefly, a midline skin incision was made on the lower back. The fifth lumbar transverse process was identified and then was separated from its muscle attachments. The underlying fourth lumbar spinal nerve was isolated and ligated with a 7-0 silk suture. The ligated nerve was then transected at the distal end. Sham-operated groups received identical surgical procedures only exposing the nerves without ligation and transection. The surgical field was then irrigated with sterile saline, and the skin incision was closed with wound clips.
Intrathecal catheter implantation in rats and drug administration
A polyethylene 10 catheter was inserted into the subarachnoid space as described. 15 After seven days of recovery, L5 SNL or sham surgery was carried out. Saline or BIX01294 (Cayman Chemical, Ann Arbor, Michigan) was intrathecally injected before surgery and once daily after surgery for seven days.
Models of morphine-induced tolerance and abnormal pain hypersensitivity
Morphine tolerance was induced in mice as described. 16 Briefly, mice received subcutaneous (s.c.) injection of morphine (20 mg/kg; WEST-WARD, Eatontown, NJ) twice daily (at a 12-h interval) for nine consecutive days in naı¨ve mice or twice daily for four consecutive days starting on day 6 post-SNL. The tail flick test as described below was performed before morphine injection and at 0.5 h after s.c. injection of an inducing dose of morphine (10 mg/kg in naı¨ve mice and 3 mg/kg in SNL mice) on mornings 1, 3, 5, and 9 in naı¨ve mice or on mornings 6, 8, and 10 after SNL. The morphine-treated time for the tail flick test was 1 h earlier than the morphine-treated time for the tolerance development in the morning. Cumulative dose-response curves were performed as described previously 16 on the afternoon of the last day. Mice received a very low morphine dose (1 mg/kg, s.c.) and the analgesic effect was assessed 30 min later by the tail flick test. Mice that were not analgesic at the first dose then received a second dose (cumulative dosing increase of 0.3 log units) and were tested 30 min afterward. The analgesic effect was observed until the mice did not show a tail flick response at the cut-off time or no further increase in tail-flick latency occurred from one dose to the next dose. Morphine-induced mechanical and thermal pain hypersensitivities in naı¨ve mice were observed as described; 16 20 mg/kg morphine were subcutaneously injected twice daily for eight days. Mechanical and thermal behavioral tests as described below were carried out prior to morphine injection and on days 1, 2, and 4 after morphine withdrawal.
Loperamide-induced tolerance and abnormal pain hypersensitivity
The protocol of loperamide tolerance in mice was modified based on the protocol in rats. 17 Loperamide hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in 6.7% 2-hydroxypropyl-b-cyclodextrin (CDEX, 20% in w/v in sterile water) and 6% dimethyl sulfoxide (DMSO). Mice received subcutaneous (s.c.) injection of loperamide (10 mg/kg) twice daily for five consecutive days in naı¨ve mice or twice daily for three consecutive days starting on day 6 post-SNL (at a 12-h interval). The paw withdrawal latency as described below was performed before loperamide injection and at 0.5 h after s.c. injection on mornings 1, 3, and 5 in naı¨ve mice or on mornings 7, 8, and 9 after SNL.
Behavioral tests
The tail flick test was carried out to observe the morphine tolerance development. A tail-flick apparatus (Model 33B Tail Flick Analgesy Meter, IITC Life Science, Woodland Hills, CA, USA) with a radiant heat source connected to an automatic timer was used to assess the analgesic response. 16 A cut-off time latency of 10 s was used to avoid tissue damage to the tail. Tailflick latencies were measured as the time required to induce a tail flick after applying radiant heat to the skin of the tail. The antinociceptive effects were expressed as the percentage of maximal possible analgesic effect (% MPAE): % MPAE ¼ [(response latency À baseline latency) / (cut-off latency À baseline latency)] Â 100%.
Mechanical behavioral test was carried out as described. 12, 13, 16, 18 Briefly, each mouse was placed in a Plexiglas chamber on an elevated mesh screen. One calibrated von Frey filament (1.47 mN; Stoelting Co., Wood Dale, IL, USA) was applied to the hind paw for approximately 1 s, and each stimulation was repeated 10 times to both hind paws. The occurrence of paw withdrawal in each of these 10 trials was expressed as a percent response frequency [(number of paw withdrawals/10 trials) Â 100 ¼ % response frequency], and this percentage was used as an indication of the amount of paw withdrawal.
Thermal behavioral test was carried out as described. 12, 13, 16, 18 In brief, each mouse was placed in a Plexiglas chamber on a glass plate. A radiant heat from Model 336 Analgesic Meter (IITC Inc./Life Science Instruments, Woodland Hills, CA, USA) was applied by aiming a beam of light through a hole in the light box through the glass plate to the middle of the plantar surface of each hind paw. When the animal lifted its foot, the light beam was turned off. The length of time between the start of the light beam and the foot lift was defined as the paw withdrawal latency. Each trial was repeated five times at 5-min intervals for each side. A cut-off time of 20 s was used to avoid tissue damage to the hind paw.
Plasmid constructs and virus production
Mouse full-length CREB (cyclic AMP response element binding protein) cDNA was synthesized and amplified from total RNA of mouse DRG using the SuperScript III One-Step RT-qPCR System with the Platinum Taq High Fidelity Kit (Invitrogen/ThermoFisher Scientific, Grand Island, NY) and primers (Table 1) . Fragments harboring CREB were ligated into pro-viral plasmids using the BspEI and NotI restriction sites. The resulting vector expressed CREB under the control of the cytomegalovirus promoter. AAV5 viral particles carrying full-length CREB cDNA were produced at the UNC Vector Core. AAV5-GFP and AAV5-Cre were purchased from UNC Vector Core (Chapel Hill, NC). HSV-GFP and HSV-G9a were provided by Dr. Eric J Nestler.
DRG neuronal culture and transfection
Primary DRG neuronal cultures and viral transfection were carried out as described. 13 Briefly, adult mice were euthanized with isoflurane and all DRG were collected in cold Neurobasal Medium (Gibco/ThermoFisher Scientific) with 10% fetal bovine serum (JR Scientific, Woodland, CA), 100 units/ml Penicillin, 100 mg/ml Streptomycin (Quality Biological, Gaithersburg, MD) and then treated with enzyme solution (5 mg/ml dispase, 1 mg/ml collagenase type I in Hanks' balanced salt solution (HBSS) without Ca 2þ and Mg 2þ (Gibco/ ThermoFisher Scientific)). After trituration and centrifugation, dissociated cells were resuspended in mixed Neurobasal Medium and plated in a six-well plate coated with 50 mg/ml poly-D-lysine (Sigma, St. Louis, MO). The cells were incubated at 95% O 2 , 5% CO 2 , and 37 C. One day later, 0.5ml of virus (titer 5 1 Â 10 12 / ml) was added to each 2-ml well. Neurons were collected two to three days later.
Reverse transcription (RT)-PCR
For quantitative real-time RT-PCR, four unilateral mouse DRG were pooled together to achieve enough RNA. Total RNA was extracted by the Trizol method (Invitrogen/ThermoFisher Scientific), treated with DNase I (New England Biolabs, Ipswich, MA), and reverse-transcribed using the ThermoScript reverse transcriptase (Invitrogen/ThermoFisher Scientific), random hexamers, and oligo (dT) primers or specific RT-primers (Table 1) . Template (1 ml) was amplified by real-time PCR using the primers listed in Table 1 (Integrated DNA Technologies). Gapdh mRNA was used as an internal control for normalization. Each sample was run in triplicate in a 20 ml reaction with 250 nM forward and reverse primers, 10 ml of SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and 20 ng of cDNA. Reactions were performed in a BIO-RAD CFX96 real-time PCR system. Ratios of ipsilateral-side mRNA levels to contralateralside mRNA levels were calculated using the ÁCt method (2
ÀÁÁCt
). All data were normalized to gapdh mRNA, which has been demonstrated to be stable even after peripheral nerve injury insult. 12, 13 For single-cell RT-PCR, freshly dissociated mouse DRG neurons were first prepared as described previously. 13, 18 Briefly 4 h after plating, a single living small DRG neuron was collected under an inverted microscope fit with a micromanipulator and microinjector and placed in a PCR tube with 5-10 ml of cell lysis buffer (Signosis, Sunnyvale, CA). After centrifugation, the supernatants were collected. The remaining real-time RT-PCR procedure was carried out according to the manufacturer's instructions with the single-cell real-time RT-PCR assay kit (Signosis). All primers used are listed in Table 1 .
Chromatin immunoprecipitation (ChIP) assay
The ChIP assays were conducted using the EZ ChIP Kit (Upstate/EMD Millipore, Darmstadt, Germany) as 
RT: Reverse-transcription. F: Forward. F1-5: Fractions 1-5. R: Reverse. N-PCR: Nested PCR. Underlined letters: the restriction enzyme recognition sites.
described. 13 The homogenization solution from DRG was crosslinked with 1% formaldehyde for 10 min at room temperature. The reaction was terminated by the addition of 0.25 M glycine. After centrifugation, the collected pellet was lysed by SDS lysis buffer with protease inhibitor cocktail and sonicated until the DNA was broken into fragments with a mean length of 200 to 1000 bp. The fragment sizes were verified by gel electrophoresis (data not shown). After the samples were precleaned with protein G agarose, they were subjected to immunoprecipitation overnight with 2 mg of rabbit antibodies against G9a (Abcam, Cambridge, MA), CREB (Abcam), and H3K9me2 (Abcam), or with 2 mg of normal rabbit serum overnight at 4 C. Input (10%-20% of the sample for immunoprecipitation) was used as a positive control. The DNA fragments were purified and identified using PCR/Real-time PCR with the primers listed in Table 1 .
Single-or double-labeled immunohistochemistry
Mice were anesthetized with isoflurane and perfused with 4% paraformaldehyde before being analyzed by singleor double-labeled immunohistochemistry. L3 and L4 DRG were removed, post-fixed, and dehydrated before frozen sectioning at 20 mm. After the sections were blocked for 1 h at room temperature in 0.01 M PBS containing 10% goat serum and 0.3% Triton X-100, they were incubated with the following one or two primary antibodies over one or two nights at 4 C. The antibodies include rabbit anti-G9a (1:20, Abcam), mouse anti-CREB (1:100, Cell Signaling, Danvers, MA), guinea pig anti-MOR (1:1,000, EMD Millipore, German), and rabbit anti-KOR (1:200, Novus Biologicals, Littleton, CO). The sections were then incubated with either goat anti-rabbit antibody conjugated to Cy3 (1:200, Jackson ImmunoResearch, West Grove, PA), or goat anti-mouse antibody conjugated to Cy2 (1:200, Jackson ImmunoResearch) or goat anti-guinea pig antibody conjugated to Cy3 (1:200, Jackson ImmunoResearch) for 2 h at room temperature. Control experiments included substitution of normal mouse or rabbit serum for the primary antiserum and omission of the primary antiserum. All immunofluorescence-labeled images were examined using a Leica DMI4000 fluorescence microscope and captured with a DFC365FX camera (Leica, Germany). Single-or double-labeled neurons were quantified manually or by using NIH Image J Software.
Western blotting
Two unilateral mouse DRGs were pooled to reach a suitable total protein concentration. Tissues were homogenized and the cultured cells ultrasonicated in chilled lysis buffer (10 mM Tris, 1 mM phenylmethylsulfonyl fluoride, 5 mM MgCl 2 , 5 mM EGTA, 1 mM EDTA, 1 mM DTT, 40 mM leupeptin, 250 mM sucrose). After centrifugation at 4 C for 15 min at 1,000 g, the supernatant was collected for cytosolic proteins and the pellet for nuclear proteins. The contents of the proteins in the samples were measured using the Bio-Rad protein assay (Bio-Rad) and then the samples were heated at 99 C for 5 min and loaded onto a 4%-15% stacking/7.5% separating SDS-polyacrylamide gel (Bio-Rad). The proteins were then electrophoretically transferred onto a polyvinylidene difluoride membrane (Bio-Rad). After the membranes were blocked with 3% nonfat milk in Trisbuffered saline containing 0.1% Tween-20 for 1 h, the following primary antibodies were used: rabbit anti-MOR (1:500, Neuromics, Minneapolis, MN), rabbit anti-KOR (1:500, Santa Cruz, Dallas, Texas), rabbit anti-GAPDH (1:1,000, Santa Cruz), rabbit anti-CREB (1:1,000, Abcam), mouse anti-phospho-CREB (Ser133) (1:1,000, EMD Millipore), mouse anti-a-tublin (1:1,000, Santa Cruz), rabbit anti-G9a (1:1,000, Cell signaling), rabbit anti-H3K9me2 (1:500, EMD Millipore), and rabbit anti-histone H3 (1:1,000, Cell Signaling), The proteins were detected by horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:3,000, Jackson ImmunoResearch) and visualized by western peroxide reagent and luminol/enhancer reagent (Clarity Western ECL Substrate, Bio-Rad) and exposure by ChemiDoc XRS System with Image Lab software (Bio-Rad). The intensity of blots was quantified with densitometry using Image Lab software (Bio-Rad). All cytosol protein bands were normalized to either bactin, a-tubulin, or GAPDH, whereas all nucleus protein was normalized to total histone H3.
Whole-cell patch clamp recording on spinal cord slices
Adult mouse spinal cord slices were prepared as described. 19 Briefly, mice (age >24 days) were deeply anesthetized with isoflurane. Laminectomy was applied from mid thoracic to lower lumbar levels. The spinal cord was quickly removed and placed in cold modified artificial cerebrospinal fluid (ACSF) containing: (in mM) 80 NaCl, 2. Whole-cell patch recording was carried out as described. 19 The slice was transferred to a recording chamber (Warner Instruments, Hamden, CT) and perfused with oxygenated recording solution at a rate of 3 ml/min at room temperature. Neurons were identified by infrared differential interference contrast (IR-DIC) with an upright microscope DM6000 (Leica) equipped with a 40 Â 0.80 NA water-immersion objective and a CCD camera (Leica). Whole-cell patch clamp recording was carried out in the voltage-clamp mode. The electrode resistances of micropipettes ranged from 3 to 8 MV. Lamina II neurons were clamped with an Axopatch-700B amplifier (Molecular Devices, Downingtown, PA). The intracellular pipette solution contained: (in mM) 110 Cs 2 SO 4 , 5 TEA-Cl, 0.5 CaCl 2, 2 MgCl 2, 5 EGTA, 5 HEPES, 5 TEA, 5 MgATP, 0.5 NaGTP, and 1 GDP-b-S. Cs, and TEA was used as a K þ -channel blocker and GDP-b-S used as a GTP binding protein blocker to prevent the postsynaptic m-opioid mediated effect as previously described. [20] [21] [22] To record mEPSC, 500 nM TTX was presented at the recording solution as described above. To record eEPSC, a suction electrode (A-M systems) was used for electrical stimulation of the attached dorsal root. Stimulation was delivered by the suction electrode with a constant current stimulator S88 (Grass, Rockland, MA). To verify different primary afferent inputs, Ab fiber-evoked EPSCs were classified as monosynaptic by constant latency and absence of failures upon 25 mA/20 Hz stimulation; Ad fiber-evoked EPSCs were classified as monosynaptic by constant latency and absence of failures upon 100 mA/2 Hz stimulation; C fiber-evoked EPSCs were classified as monosynaptic by absence of failures upon 500 mA/1 Hz stimulation. The conduction velocity was further measured to distinguish the primary afferent input (C < 0.8 m/s). 23, 24 Only C fiber input monosynaptic neurons were measured for further experiments. Measurements were made from only one neuron per slice. The pair pulse protocol was delivered by S88 with 20 Hz frequency and 50 ms pulse interval. The signals were filtered at 2 k Hz. Data were stored on computer by a DigiData 1500 interface and were analyzed by the pCLAMP 10.4 software package (Molecular Devices). All experiments were performed at room temperature.
Statistical analysis
For in vitro experiments, the cells were evenly suspended and then randomly distributed in each well tested. For in vivo experiments, the animals were distributed into various treatment groups randomly. All of the results are given as means AE SEM. The data were statistically analyzed with two-tailed, paired Student's t test and a one-way or two-way ANOVA. When ANOVA showed a significant difference, pairwise comparisons between means were tested by the post hoc Tukey method (SigmaPlot 12.5, San Jose, CA). Significance was set at p < .05.
Results
G9a is responsible for nerve injury-induced reductions of MOR, KOR, and DOR in DRG
Peripheral nerve injury increases G9a expression and decreases the expression of MOR, KOR, and DOR in the injured DRG. [4] [5] [6] [7] 25 To determine whether the increased G9a participated in the downregulation of these three opioid receptors in the DRG following peripheral nerve injury, we carried out a preclinical mouse model of unilateral fourth lumbar (L4) SNL.
14 AAV5-Cre was microinjected into the ipsilateral L4 DRG of G9a fl/fl mice to specifically and selectively knock down the expression of G9a. AAV5-GFP was used as a control. SNL or sham surgery was carried out 35 days after viral injection. The DRGs were harvested for RT-PCR or Western blot analysis seven days after SNL or Sham surgery. AAV5-Cre microinjection produced the deceases in basal levels of Ehmt2 mRNA (encoding G9a), G9a's two protein isoforms, and H3K9me2 in sham mice and blocked SNL-induced increases in the amounts of Ehmt2 mRNA, G9a's two protein isoforms, and H3K9me2 in the SNL mice on the ipsilateral side (Figure 1(a)-(c) ). Injection of AAV5-Cre, but not AAV5-GFP, reversed reductions of Oprm1 (encoding MOR), Oprk1 (encoding KOR), and Oprd1 (encoding DOR) mRNAs and MOR and KOR proteins in the injured DRG on day 7 post-SNL (Figure 1(a)-(c) ). AAV5-Cre injection also markedly increased basal amounts of Oprm1 mRNA and MOR and KOR proteins in the injured DRG of sham G9a fl/fl mice on day 7 (Figure 1(a)-(c) ). Similar results were observed in the injured DRG of G9a conditional knockout (G9aKO) mice that were obtained from the crossbreeding of G9a fl/fl mice with Avil Cre/þ mice (Figure 1(d) and (e)). To manipulate G9a activity in DRG, we intrathecally administered BIX-01294 (BIX, 5 mg/10ml), a specific G9a inhibitor 26 in SD rats. BIX was administered once daily for six days after SNL or sham surgery. The ipsilateral L5 DRG was harvested on day 7 post-SNL or sham surgery. As expected, pretreatment with BIX blocked the SNL-induced increase in the level of H3K9me2 in the injured DRG (Figure 1(f) ) without affecting basal levels of H3K9me2 in spinal cord and intact DRG (data not shown). BIX significantly restored SNL-induced reductions in the amounts of Oprm1, Oprk1, and Oprd1 mRNAs in the injured DRG on day 7 post-SNL (Figure 1(g) ). These results indicate that both pharmacological inhibition of DRG G9a and transgenic knockdown of DRG G9a restore the expression of three opioid receptors in the injured DRG following SNL.
To further confirm our conclusion, we examined the effect of mimicking nerve injury-induced increases in DRG G9a and H3K9me2 through microinjection of a herpes simplex virus (HSV) vector that expresses fulllength Ehmt2 (HSV-G9a) into the L3 and L4 DRG on the expression of MOR, KOR, and DOR in the DRG of naı¨ve mice. HSV-GFP was used as a control. DRG was collected for RT-PCR, Western blot, or immunohistochemical analysis on day 7 post-viral injection. Injection of HSV-G9a, but not HSV-GFP, increased the amounts of Ehmt2 mRNA, G9a's two protein isoforms, and H3K9me2 and decreased the levels of Oprm1, Oprk1, and Oprd1 mRNAs and MOR and KOR proteins in the injected DRG on day 7 post-injection (Figure 2(a) and  (b) ). The numbers of MOR-and KOR-labeled neurons were also markedly reduced in HSV-G9a-injected DRG compared to those in HSV-GFP-injected DRG ( Figure  2(c) ). Moreover, single-cell RT-PCR assay revealed the coexpression of Ehmt2 mRNA with Oprm1, Oprk1, and Oprd1 mRNAs in individual small DRG neurons ( Figure  2(d) ), suggesting that G9a directly regulates Oprm1, Oprk1, and Oprd1 gene expression. Indeed, overexpression of G9a through transduction of HSV-G9a into cultured DRG neurons not only significantly increased the levels of Ehmt2 mRNA and G9a two protein isoforms as well as H3K9me2 but also reduced the levels of Oprm1, Oprk1, and Oprd1 mRNAs and MOR and KOR proteins ( Figure  2 (e) and (f)). The evidence described above strongly fl/fl mice with microinjection of AAV5-GFP (GFP) or AAV5-Cre (Cre) into the ipsilateral L4 DRG on day 7 post-SNL or sham surgery. L, long isoform; S, short isoform. n ¼ 12 mice/group for RT-PCR and 6 mice/group for Western blots. *P < 0.05 or **P < 0.01 vs the sham mice injected with AAV5-GFP, #P < 0.05 or ##P < 0.01 vs the SNL mice injected with AAV5-GFP, one-way ANOVA followed by post hoc Tukey test. (d and e) The levels of G9a's two protein isoforms, H3K9me2, MOR and KOR in the ipsilateral L4 DRG from G9a KO mice and G9a fl/fl mice on day 7 post-SNL or sham surgery. n ¼ 12 mice/group. *P < 0.05 or **P < 0.01 vs the corresponding sham G9a fl/fl mice, ##P < 0.01 vs the corresponding SNL G9a fl/fl mice, one-way ANOVA followed by post hoc Tukey test. (f and g) The level of H3K9me2 in the ipsilateral L4 DRG (f) and the amounts of Oprm1, Oprk1, and Oprd1 mRNAs in the ipsilateral (Ipsi) and contralateral (Con) L5 DRG (g) from mice injected intrathecally with vehicle (Veh) or BIX-01294 (BIX; 2.5 mg/day for 6 days starting at the surgical day) on day 7 after SNL or sham surgery. n ¼ 6 mice/group for Western blots and 12 mice/group for RT-PCR. *P < 0.05 or **P < 0.01 vs the group treated with sham plus vehicle, #P < 0.05 or ##P < 0.01 vs the group treated with SNL plus vehicle, one-way ANOVA followed by post hoc Tukey test.
suggests the contribution of G9a to nerve injury-induced opioid receptor downregulation in the injured DRG.
Increased G9a in the DRG promotes MOR-gated primary afferent neurotransmitter release
MOR is expressed in small-diameter DRG neurons and their primary afferents, especially in peptidergic pain fibers. 27, 28 Endogenous opioids acting on MOR exert tonic inhibitory control of neurotransmitter release from these fibers. 21, 29 DRG MOR downregulation augments the release of primary afferent neurotransmitters in neuropathic pain. 30 ,31 Thus, we tested whether mimicking the nerve injury-induced DRG G9a increase altered MOR-gated primary afferent neurotransmitter release. We measured the changes in miniature excitatory postsynaptic current (mEPSC) frequencies, which reflected the alteration in presynaptic neurotransmitter release, 32, 33 in lamina II neurons from L3/4 spinal cord slices of mice subjected to injection of HSV-G9a or control HSV-GFP into the ipsilateral L3/4 DRG. The slices were collected five to seven days after DRG microinjection. mEPSC frequency in the HSV-G9a-treated group was significantly higher than that in the control group (Figure 3(a) and (b) ), although the mEPSC amplitude was similar between the two groups (Figure 3(a) and (c) ). To verify whether this alteration is due to the reduction of MOR function in primary afferents, we applied the selective MOR agonist DAMGO. 1mM of DAMGO led to a greater decrease in mEPSC frequency from the control group (43.37 AE 4.05%) than that from the HSV-G9a treated group (19.62 AE 3.79%), although it did not alter the mEPSC amplitude (Figure 3(a)-(c) ). This effect was abolished after DAMGO wash out (Figure 3(a) ) or by the addition-prior to DAMGO treatment-of the selective MOR antagonist CTOP (data not shown). This evidence suggests that increased G9a expression in DRG results in an increase in MOR-gated presynaptic neurotransmitter release. The amounts of Ehmt2, Oprm1, Oprk1, and Oprd1 mRNAs (e) and G9a's two protein isoforms, MOR, KOR, and H3K9me2 proteins (f) in the cultured DRG neurons transduced with HSV-G9a or HSV-GFP. n ¼ 3 repeats. *P < 0.05 or **P < 0.01 vs the corresponding AAV5-GFP-treated group by two-tailed paired t-test.
The mEPSCs recorded above may reflect overall excitatory inputs from both primary afferents and interneurons to the recorded neurons. 33 To further examine the role of G9a in the release of primary afferent neurotransmitters, we recorded the EPSCs evoked by stimulation of the dorsal root (C-fiber: 500 mA intensity and 1 Hz) with a paired pulse protocol. The pair-pulse ratio (PPR), which reflects the probability of primary afferent neurotransmitter release, 32, 33 was determined by dividing the second peak amplitude by the first one. PPR significantly declined in the HSV-G9a treated group compared to the control group (Figure 3(d) and (e) ). Additionally, the first peak amplitude of the EPSC in the HSV-G9a treated group was higher than that in the control group (Figure 3(d) and (f) ). 1mM DAMGO application markedly increased the PPR by 21.24% and decreased the first peak amplitude by 48.99% in the control group, but only 12.43% and 23.31%, respectively, in the HSV-G9a treated group (Figure 3(d)-(f) ). DAMGO effects could be abolished after its wash out (Figure 3(d) ) or by prior treatment with CTOP (data not shown). These results further demonstrate that increased G9a in DRG promotes neurotransmitter release from primary afferent terminals through presynaptic MOR downregulation in DRG.
Blocking DRG G9a expression improves MOR mediated analgesia, tolerance, and hyperalgesia
We also defined whether MOR-mediated morphine analgesia and tolerance and pain hypersensitivity could be affected by DRG G9a. Given that G9a knockout increased basal expression of MOR in DRG (Figure 1(b)-(e) ), we first observed the effect of this knockout on morphine analgesia and morphine-induced tolerance and pain hypersensitivity in naı¨ve mice. For the analgesic effects, thermal test were carried out prior to morphine injection and 30 min after morphine injection five weeks after viral microinjection into the unilateral DRG of G9a fl/fl mice. Injection of AAV5-Cre (but not control AAV5-GFP) into unilateral L3/4 DRG of G9a fl/ fl mice robustly increased morphine's MPAE on the ipsilateral (not contralateral) side after subcutaneous (s.c.) administration of a single low dose of morphine Effect of DAMGO (1 mM) on mEPSC frequencies in the HSV-GFP-injected group (n ¼ 21 neurons, 13 mice) and the HSV-G9a-injected group (n ¼ 21 neurons, 14 mice). *P < 0.05 vs the HSV-GFP-injected group before DAMGO; ##P < 0.01 vs the HSV-GFP-injected group after DAMGO, one-way ANOVA followed by post hoc Tukey test. (c) mEPSC amplitude was not altered in both groups before and after DAMGO application. (d) Examples of traces of the C-fiber input recorded before and after DAMGO (1 mM) application and after DAMGO washout. (e) Pair pulse ratio (PPR) was significantly decreased in the HSV-G9a-injected group (n ¼ 23 neurons, 19 mice) compared to that in the HSV-GFP-injected group (n ¼ 23 neurons, 20 mice) before DAMGO. DAMGO significantly increased the PPR in the HSV-GFP-injected group, but not in the HSV-G9a-injected group. *P < 0.05 or **P < 0.01 vs the HSV-GFP-injected group before DAMGO, one-way ANOVA followed by post hoc Tukey test. (f) The first peak amplitude was significantly increased in the HSV-G9a-injected group compared to the HSV-GFP-injected group before DAMGO. DAMGO dramatically decreased the first peak amplitude in the HSV-GFP-injected group compared to the HSV-G9a-injected group. *P < 0.05 or **P < 0.01 vs the HSV-GFPinjected group before DAMGO, one-way ANOVA followed by post hoc Tukey test.
(1 mg/kg) (Figure 4(a) ). The morphine-induced pain hypersensitivity was examined five weeks after viral injection. Consistent with previous studies, 16, 34 mechanical allodynia, as indicated by the increase in paw withdrawal frequency to von Frey hair stimulation, and thermal hyperalgesia, as indicated by the decrease in paw withdrawal latency to heat stimulation, developed one day after morphine withdrawal in AAV5-GFPtreated G9a fl/fl mice that received repeated injections of s.c. morphine (20 mg/kg, twice daily for eight days) (Figure 4(b) and (c) ). In contrast, the AAV5-Cre-treated G9a fl/fl mice failed to display these pain hypersensitivities (Figure 4(b) and (c) ). The morphine analgesic tolerance was examined in G9aKO mice. G9a fl/fl mice served as a control group. Repeated s.c. injection of morphine (20 mg/kg, twice daily for eight days) produced morphine analgesic tolerance to a relative low dose of morphine (10 mg/kg) as indicated by time-dependent decreases in morphine MPAEs in control G9a fl/fl mice, but not in the G9aKO mice (Figure 4(d) ). The ED 50 value of morphine in the G9aKO mice (5.4 mg/kg) was substantially smaller than that in control G9a fl/fl mice (9.7 mg/kg) on the last day after repeated s.c. administration of morphine (Figure 4(e) ). Furthermore, we examined whether rescuing MOR downregulation by blocking the nerve injury-induced DRG G9a increase improved morphine analgesia and alleviated morphine-induced tolerance under neuropathic pain conditions. When the first test dose of morphine (3 mg/kg) was administered s.c. on day 6 after SNL, morphine MPAE was much greater in the G9aKO mice than that in control G9a fl/fl mice ( Figure  4(f) ). Repeated s.c. morphine administration twice daily (20 mg/kg) for four days starting from day 6 after SNL also led to a time-dependent reduction in morphine MPAE in control SNL G9a fl/fl mice (Figure 4(f) ), but this reduction was significantly less in the SNL G9aKO mice (Figure 4(f) ). The ED 50 value of morphine was 4.1 mg/kg in the G9aKO mice and 7.2 mg/kg in control G9a fl/fl mice on day 10 post-SNL (Figure 4(g) ). Taken together, blocking DRG G9a expression improved morphine analgesia and prevented morphine analgesic tolerance development under neuropathic pain conditions. fl/fl mice and G9aKO mice that received repeated morphine injections (20 mg/kg, s.c. twice daily for 8 days). MPAE, maximal possible analgesic effect. n ¼ 5-6 mice/group. **P < 0.01 vs the corresponding G9a fl/fl mice, two-way ANOVA followed by post hoc Tukey test. (e) The cumulative dose-response curves of morphine in naïve G9a fl/fl mice and G9aKO mice on day 9 after repeated morphine injections as described above. n ¼ 5-6 mice/group. (f) Time course of morphine-induced analgesia in the SNL G9a fl/fl mice and G9aKO mice that received repeated morphine injections (20 mg/kg, s.c. twice daily for 4 days starting on day 6 after SNL). n ¼ 5-6 mice/group. **P < 0.01 vs the corresponding G9a fl/fl mice, two-way ANOVA followed by post hoc Tukey test. (g) The cumulative dose-response curves of morphine in the SNL G9a fl/fl mice and G9aKO mice that received repeated morphine injections as described above.
To specify DRG G9a regulation on peripheral MOR function, we used a peripheral MOR agonist, loperamide, which cannot pass through the blood-brain barrier. 35 The loperamide analgesic effects and its analgesic tolerance were examined five weeks after DRG viral injection in G9a fl/fl mice. For the analgesic effects, thermal test was carried out before and 30 min after loperamide injection. A low dose of lopermide (2.5 mg/kg, s.c.) produced a dramatic increase in MPAE in the AAV5-Cre injected naı¨ve G9a fl/fl mice compared to control AAV5-GFP injected naı¨ve G9a fl/fl mice on the ipsilateral side ( Figure 5(a) ). Similar small analgesic effects were seen on the contralateral side in both injected mice ( Figure 5(b) ). A specific MOR antagonist naltrexone (5 mg/kg, i.p.), which was given 30 min before loperamide administration, could significantly block these effects on the ipsilateral and contralateral sides of both injected mice (Figure 5(a) and (b) ). Consistent with a previous report, 17 loperamide analgesic tolerance developed after its systemic and repeated administration (10 mg/kg, twice daily for five days, s.c.) on both microinjected naı¨ve G9a fl/fl mice ( Figure 5(c) and (d) ). Although the first dose of loperamide produced similar analgesic effects in both microinjected mice, MPAEs decreased at a slower rate in the AAV5-Cre injected mice than that in the AAV5-GFP-injected mice on days 3 and 5 postinjection of loperamide on the ipsilateral side ( Figure 5(c) ). Similarly, loperamide analgesic tolerance also developed after its systemic and repeated administration (10 mg/kg, twice daily for three days, s.c.) starting on day 7 post-SNL in both microinjected mice. However, the values of MPAEs in the AAV5-Cre injected mice were markedly higher than those in the AAV5-GFP-injected mice on days 7, 8, and 9 post-SNL ( Figure 5(e) ). These data suggest that rescuing DRG MOR reduction by blocking increased G9a in the injured DRG increases peripheral MOR-triggered analgesic effects and delays the development of peripheral MOR-mediated analgesic tolerance.
Increased G9a blocks the access of CREB to its binding motifs within the Oprm1 gene in the injured DRG after SNL What is the mechanism by which G9a is involved in DRG MOR reduction under neuropathic pain conditions? We first used ChIP assays and found that G9a binds to two fragments (À450/À288 bp and þ142/ þ312 bp) of the Oprm1 gene as demonstrated by the amplification of only these two regions (out from fl/fl mice with microinjection of AAV5-GFP or AAV5-Cre into unilateral L4 DRGs that received repeated loperamide injections (10 mg/kg, s.c. twice daily for 3 days starting on day 7 after SNL). n ¼ 5 mice/group. **P < 0.01 vs the corresponding AAV5-GFP-injected group, two-way ANOVA followed by post hoc Tukey test.
5 regions from À450 to þ312 bp) from the complexes immunoprecipitated with G9a antibody in nuclear fractions from sham DRG (Figure 6(a) ). These binding activities strikingly increased in the injured DRG on day 7 after SNL, but not after sham surgery (Figure 6(b) ). Similar increased bindings of H3K9me2 were also observed in the injured DRG on day 7 after SNL ( Figure 6(c) ). H3K9me2 binding to these fragments was dependent on G9a expression because DRG G9aKO abolished SNL-induced increases in this binding in SNL mice (Figure 6(c) ).
We then determined whether the increased G9a/H3K9me2 binding affected the interactions of the Oprm1 gene with its transcription factors. The online software (TFSEARCH) prediction revealed a binding motif (þ195/þ202) of CREB within the 5 0 -end untranslated region of the gene. ChIP assay confirmed the binding of CREB within this region in the nuclear fractions from DRG after sham surgery or cultured DRG neurons transduced with control AAV5-GFP (Figure 6 (d) and 6(e)). This binding was reduced on day 7 following SNL as shown by a 37% reduction in band density in the ipsilateral L4 DRG from the SNL mice compared to that from the sham mice ( Figure 6(d) ). Consistently, mimicking the SNL-induced increase in DRG G9a in cultured DRG neurons by overexpressing G9a using HSV-G9a abolished the binding of CREB to its binding motif within the Oprm1 gene ( Figure 6(e) ). Furthermore, overexpressing CREB via AAV5-CREB in cultured DRG neurons significantly increased levels of MOR protein ( Figure 6(f) ). This increase was substantially attenuated by coinfection with HSV-G9a (Figure 6(f) ). Given that CREB is coexpressed with G9a and MOR in individual DRG neurons (Figure 6(g) ), we conclude that the SNL-induced DRG G9a increase leads to the enrichment of H3K9me2 at the specific sites of the Oprm1 gene, resulting in the blockade of CREB binding to its binding motif within the gene and the silencing of Oprm1 gene in the injured DRG under neuropathic pain conditions. Interestingly, this blockade of CREB binding to the Oprm1 gene is persistent despite the fact that SNL time-dependently increases the amounts of CREB and its phosphorylated counterpart in the injured DRG ( Figure 6(h) ).
Discussion
This study provides the evidence that nerve injuryinduced increases in G9a and H3K9me2 are responsible for epigenetic silencing of not only Oprm1 gene but also Oprk1 and Oprd1 genes in the injured DRG. Mimicking these increases downregulated the expression of three opioid receptors in the DRG and promoted the MORgated release of primary afferent neurotransmitters. Conversely, blocking these increases rescued DRG Oprm1, Oprd1, and Oprk1 gene expression, restored the nerve injury-induced decrease in morphine or loperamide analgesia, and prevented the development of morphine or loperamide-induced analgesic tolerance under neuropathic pain conditions. Mechanistically, nerve injury produced an increase in the binding activity of G9a and H3K9me2 to the Oprm1 gene, which was associated with reduced binding of CREB to the Oprm1 gene in the injured DRG. Thus, G9a participates in the nerve injury-induced reduction of MOR likely through G9a-triggered blockage in the access of CREB to the Oprm1 gene.
G9a as a repressor of gene expression participates in the nerve injury-induced reduction of opioid receptors in the injured DRG. A recent study reported that G9a was required for nerve injury-induced downregulation of the Oprm1 gene in the injured DRG. 11 Nerve injury increased the enrichment of H3K9me2 in regions (À43/ þ63 bp, À411/À302 bp, and þ376/þ495 bp) of the Oprm1 gene in the DRG.
11 G9a inhibition or knockdown rescued MOR expression in the injured DRG and morphine analgesic effects reduced by SNL. 11 However, whether G9a also regulates other opioid receptors is unknown. Furthermore, the mechanism of how G9a is involved in nerve injury-induced DRG Oprm1 gene silencing is unclear. We demonstrated here that G9a was essential for epigenetic silencing of not only the Oprm1 gene but also Oprk1 and Oprd1 genes in the injured DRG under neuropathic pain conditions. SNL-induced reductions of these opioid receptors could be rescued by G9a knockdown/knockout in the injured DRG and mimicked by DRG G9a overexpression. Moreover, DRG G9a knockdown/knockout restored the nerve injury-induced decrease in morphine or loperamide analgesia and prevented the development of morphine or loperamide-induced analgesic tolerance following SNL, whereas DRG G9a overexpression enhanced the MOR-gated release of primary afferent neurotransmitters. Mechanistically, G9a binds to only two regions (À450/À288 bp and þ142/þ312 bp) out of five regions (from À450 bp to þ312 bp) of the Oprm1 gene. SNL increased the binding activity of G9a and H3K9me2 to these two regions. These findings suggest that the increased enrichment of histone methylation by G9a is distributed in specific sites within the promoter and 5
0 -end untranslated regions of the Oprm1 gene following SNL. The distinct binding sites of H3K9me2 observed between the present study and a previous study 11 may be due to species difference (mouse vs rat). It should be noted that other histone methyltransferases such as SUV39H1 may be responsible for the production of H3K9me2 after SNL. 36 We further found that the increased binding of G9a/ H3K9me2 to the Oprm1 gene was associated with the decreased binding of CREB to its motif within the
